Member Info for Nolupus

Supermobileman,

I think that we are going around in circles so whatever ... You know it all as usual so believe what you want , no skin off my back .

Supermobileman,

I think you should take a bit of time to look things up on the french company house , before saying anything nasty about my mental health...

Au revoir

Btw supermobileman,

Immupharma biotech was established in 2000 ...

I can't see how Tim "created" it , when he joined IMM much later but whatever...

Supermobileman,

I think you should maybe practice what you preach 🧐

If you crack two eggs , you make an omelette

Very impressed by his creation 😋

Supermobileman,

You seem to be very impressed by our CEO but there are a few " facts" that are a bit misleading in your post,imo

- Tim didn't " create " Immupharma Bordeaux as you say , just changed the name from Ureka which has been around for quite a while and was founded by Gilles Guichard and Robert Zimmer.

- The fundraise which you mention of £10 million just before the " delayed " readout of the last P3 trial probably did save IMM , but you forget to mention that more than £ 2.25 million of that money was "invested " into Tim's other company Incanthera which resulted in a huge loss to IMM .

Two sides to every coin but whatever, facts are facts

The lights are still on, and Tim at 69 is CEO and Chairman

Que sera sera , whatever will be , will be.....

Pebsi,

So you are still in the view that Avion will be conducting and paying up to $25 million to finance that New P3 trial ??

Outside of lupus, the Licence and Development Agreement also includes the option for Avion to explore the peptide's potential in other auto-immune diseases for the US market.

Extract from the november 2019 RNS ...

IMM don't seem to want to communicate on what is the current situation with Avion but one has to read between the lines ...

Everyone to their own convictions as per usual ..

@ alesia or whatever strong buy nickname you have

I don't know you and you don't know me or anything else , so please refrain from personal commentary

Could you possibly point out any non factual commentary i have made ?

Sound advice...Dyor and decipher what is reality and what is just pure speculation.

Always keep an open mind and know that there is always two sides to every coin.

AIM is a roller coaster so one should expect the downs whilst trying to anticipate the highs .

Wigwammer,

Once again , I said that you were wrong to state that IMM have a " late stage asset " , I never said that they had no assets 🧐

Anyway , you have dropped the " late stage" part from your last few posts , so therefore you have got AI to confirm that point 😉

Wigwammer,

No bitterness from my side, I just like things to be factual and not twisted to suit your agenda .

Calling people names and using abrasive remarks to try and discredit other people ( and their points of views ) is not kosher .

Wigwammer,

You may of course be the best p&d on IMM and make a fortune on the roller coaster but that doesn't mean that you are always right.

IMM have no ongoing clinical trial and have asked and received " guidance" from the FDA in the past but to be considered as a late stage asset , one would have to be close to the approval stage, yet nothing in the clinical stage at this time ...

Wigwammer,

Once again, I have to disagree with you

IMM have no late stage asset at this time and saying that the FDA do regard P140 as one is highly misleading , imo

IMM have no ongoing clinical trial at this time , so how can you say that they have a late stage asset ?

One should not forget that the Ceo's job is to keep the lights on so that the company can pursue it's activities...

Jam tomorrow, billion dollar markets , etc etc are part of the game , especially when you need to raise again and again whilst never delivering anything tangible for your shareholders.

Only time will tell if a Real deal will be signed and that a major company will invest the REAL money in developing the P140 program but in the meantime the lights are still on .

A chip and a chair .

Why not annonce what is the situation with Avion is my question ?

No mention of them for quite some time so why keep shareholders in the dark ?

A valid point from validpoint 👍

ImmuPharma will also receive $5 million for each additional approval, other than lupus, as Avion also has the rights, for the US, to explore further opportunities within Lupuzor™'s peptide platform for other auto-immune indications outside of lupus

Halfbutt,

Funny you should mention 2018, because reading the board brings us right back to the first quarter of 2018 🙃

" Eyes to the stars but keep the feet on the ground "

Best regards to the missus 😉

Rookie1,

Without knowing more about the prevelance of Type M immune disorders and without having any specific treatment (yet on the market ) do you really think that doctors will be requesting a diagnostic test ??

These things take a long time so let's not put the horse before the cart 😏

Best regards